EZH1/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types

Huageng Huang1, Xinyi Deng2, Le Yu3

  • 1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China.

Abstract

No abstract available in PubMed .

Related Concept Videos